In my clinical practice, one of the most frequent conversations I have with patients revolves around over-the-counter supplements.
Patients are often looking for non-prescription options to support mood, anxiety, or focus. Unfortunately, the wellness industry is largely unregulated, filled with adulterated products, and marketed with inflated claims. Many patients take supplements without informing their physicians—unaware that certain "natural" compounds carry significant risk of organ toxicity or dangerous interactions with prescription medications.
Below is an evidence-based breakdown of common psychiatric supplements: those backed by strong clinical trials, those reserved for specific niches, and those that should be approached with extreme caution or avoided entirely.
As a reminder, these compounds are supplements, meaning that they cannot or should not replace standard medical and psychiatric treatments. They are supplementary - it's literally in the name!
Looking for practitioner-grade supplements? Skip straight to Dr. Scary's curated Fullscript dispensary to view third-party tested, physician-vetted formulations.
Browse Dr. Scary’s Dispensary (10% Discount Applied) →Tier 1: Strong Clinical Evidence & High Safety Profiles
1. High-EPA Omega-3 Fatty Acids (Fish Oil)
- Primary Target: Major Depressive Disorder, Mood Instability, Neuroinflammation.
- The Clinical Evidence: Omega-3 fatty acids—specifically eicosapentaenoic acid (EPA)—modulate neuroinflammatory cytokines and improve neuronal cell membrane fluidity. Meta-analyses and psychiatric guidelines (such as those for borderline personality and mood disorders) indicate that formulas with a high ratio of EPA to DHA (at least 2:1, with ≥1,000mg total EPA daily) act as effective augmentation strategies for depression and emotional dysregulation.
- Clinical Note: Standard drug-store fish oils often contain low concentrations of active EPA or are oxidized (rancid). Opt for third-party tested, practitioner-grade formulations.
2. Silexan (Standardized Lavender Essential Oil, 80mg–160mg)
- Primary Target: Generalized Anxiety Disorder (GAD), Subthreshold Anxiety, Sleep Architecture.
- The Clinical Evidence: Silexan is a proprietary German oral lavender preparation that acts via pre-synaptic voltage-gated calcium channel inhibition and 5-HT1A receptor modulation. Double-blind randomized controlled trials (RCTs) have shown that 80mg daily of Silexan demonstrates anxiolytic efficacy comparable to low-dose lorazepam (0.5mg) or paroxetine (20mg) without sedation, dependence, or withdrawal effects.
- Clinical Note: This applies strictly to oral Silexan softgels (e.g., CalmAid), not topical essential oils, which should never be ingested.
3. Low-Dose Lithium Orotate (1mg–5mg)
- Primary Target: Cognitive Resilience, Synaptic Density, Neuroprotection, Mood Regulation.
- The Clinical Evidence: Research from Harvard Medical School highlighted that trace lithium depletion in brain tissue is an early feature of cognitive decline and neurodegeneration. Micro-doses of lithium orotate bypass amyloid-beta trapping to support synaptic connections and quiet neuroinflammation without the renal or thyroid toxicity associated with high-dose prescription lithium carbonate (300mg+).
4. L-Methylfolate (15mg)
- Primary Target: Treatment-Resistant Depression, MTHFR Polymorphisms.
- The Clinical Evidence: L-Methylfolate (marketed clinically as Deplin) is the biologically active form of Folate (Vitamin B9) that directly crosses the blood-brain barrier to act as an essential cofactor in the trimonoamine synthesis of dopamine, norepinephrine, and serotonin. It is particularly effective for patients carrying MTHFR C677T/A1298C genetic variants who cannot efficiently convert dietary folic acid.
5. Magnesium Glycinate or L-Threonate (200mg–400mg)
- Primary Target: Central Nervous System Hyperexcitability, Sleep Disruption, Somatic Anxiety.
- The Clinical Evidence: Magnesium acts as a natural physiological NMDA receptor antagonist, dampening excess neuronal excitation. Glycinate supports central calm via glycine receptor activation, while L-Threonate exhibits superior blood-brain barrier penetration for cognitive support.
6. N-Acetyl Cysteine (NAC, 1,200mg–2,400mg)
- Primary Target: Glutamate Dysregulation, OCD, Hair Pulling (Trichotillomania), SSRI Tapering "Brain Zaps."
- The Clinical Evidence: NAC modulates the cystine-glutamate antiporter (system x-c-) to normalize extracellular brain glutamate while boosting central glutathione (the brain's principal antioxidant).
Tier 2: Specialized or Niche Indications
7. Saffron Extract (30mg daily)
- Primary Target: Mild-to-Moderate Depression, SSRI-Induced Sexual Dysfunction.
- The Clinical Evidence: Multiple double-blind RCTs demonstrate that standardized saffron extract (Crocus sativus) performs comparably to low-dose fluoxetine and imipramine in mild-to-moderate depression, likely via monoamine reuptake inhibition and antioxidant pathways. It also exhibits efficacy in mitigating SSRI-associated sexual side effects.
8. Creatine Monohydrate (3g–5g daily)
- Primary Target: Bioenergetics in Major Depressive Disorder, Brain Energy Metabolism.
- The Clinical Evidence: Brain imaging shows altered phosphocreatine levels in patients experiencing major depression. Supplementation enhances brain energy reserves, with clinical trials showing accelerated response times when combined with standard SSRI therapy (particularly in female patients).
9. L-Theanine (100mg–200mg)
- Primary Target: Acute Stress, Mind-Racing Insomnia, Jitteriness from Caffeine.
- The Clinical Evidence: An amino acid found in green tea, L-Theanine crosses the blood-brain barrier to increase alpha brain-wave activity (relaxed alertness) and block glutamate binding to AMPA receptors.
10. Vitamin D3 (2,000 IU – 5,000 IU)
- Primary Target: Seasonal Affective Disorder (SAD), Depressive Symptoms Secondary to Deficiency.
- The Clinical Evidence: Vitamin D acts as a neurosteroid that regulates gene expression for serotonin synthesis via tryptophan hydroxylase 2 (TPH2). Checking serum 25-hydroxyvitamin D levels is a standard psychiatric baseline, with repletion showing clear mood benefits in deficient individuals.
Tier 3: Use with Caution (Strict Warnings Required)
11. SAMe (S-Adenosylmethionine)
- Clinical Utility: Potent methyl donor with solid trial evidence for unipolar depression.
- CRITICAL SAFETY WARNING: SAMe must never be used in patients with known or suspected Bipolar Disorder, as it carries an exceptionally high risk of triggering acute mania or hypomania. Additionally, patients with Parkinson’s Disease should avoid SAMe, as prolonged administration can deplete central dopamine reserves and exacerbate motor symptoms.
12. St. John's Wort (Hypericum perforatum)
- Clinical Utility: Widely prescribed in Europe for mild depression with robust clinical backing.
- CRITICAL SAFETY WARNING: St. John's Wort is a potent inducer of hepatic CYP3A4 enzymes and P-glycoprotein. It dramatically reduces blood levels of oral contraceptives (causing breakthrough pregnancy), oral anticoagulants, antiretrovirals, and immunosuppressants. When combined with prescription antidepressants, it carries a high risk of precipitating Serotonin Syndrome.
13. 5-HTP (5-Hydroxytryptophan)
- Clinical Utility: Marketed for PMDD, mood regulation, and sleep onset.
- CRITICAL SAFETY WARNING: Because 5-HTP bypasses the body's rate-limiting enzyme (tryptophan hydroxylase), it floods central and peripheral serotonin pathways indiscriminately. Combining 5-HTP with SSRIs or SNRIs poses a severe risk of Serotonin Syndrome. Long-term use can also deplete catecholamines (dopamine and norepinephrine).
Tier 4: Not Recommended / Avoid in Psychiatric Practice
14. Ashwagandha (Withania somnifera)
- Why We Avoid: Despite intense social media marketing for cortisol reduction, Ashwagandha carries increasing reports of drug-induced liver injury (DILI), subclinical thyroid stimulation (worsening hyperthyroidism), and a recognized clinical phenomenon of emotional blunting ("anhedonia") following sustained use.
15. Kratom (Mitragyna speciosa)
- Why We Avoid: Marketed as a natural herbal tea for anxiety and pain, Kratom contains active alkaloids (mitragynine) that act as partial mu-opioid receptor agonists. It carries a high risk of physiological dependence, severe opioid-like withdrawal, drug-induced liver injury, and psychosis at higher doses.
16. Kava Kava (Piper methysticum)
- Why We Avoid: Although Kava modulates GABA-A receptors to relieve acute anxiety, it is linked to unpredictable, severe hepatotoxicity (fulminant liver failure). Safer, evidence-backed alternatives like Silexan make Kava medically unjustifiable.
17. Phenibut
- Why We Avoid: A potent GABA-B agonist often hidden in online "nootropic" stacks. Phenibut rapidly induces tolerance within days, leading to physical dependence and severe, potentially dangerous withdrawal symptoms (rebound panic, hallucinations, and seizures) that mirror alcohol or benzodiazepine withdrawal.
Accessing Practitioner-Grade Mental Health Formulations
Over-the-counter retail supplements often suffer from poor quality control, heavy metal contamination, and inaccurate active ingredient dosing. Dr. Scary maintains a curated dispensary of third-party tested, clinical-grade nutraceuticals.
| CATEGORY | FEATURED FORMULATION | TARGETED CLINICAL PURPOSE | QUALITY ASSURANCE |
|---|---|---|---|
| Anxiety & Calm | Silexan (Lavender 80mg) | Anxiolytic support without sedation or habituation. | Standardized active linalool/linalyl acetate |
| Mood & Cytokine Support | High-EPA Omega-3s | Neuronal membrane fluidity & central inflammation modulation. | Third-party tested, cold-chain shipped |
| Cognitive & Neuroprotective | Lithium Orotate (5mg) | Trace mineral support for synaptic density & mood resilience. | Purified, low-dose chelated form |
Physician Quality Guarantee: All orders placed through Dr. Scary's Fullscript dispensary are sourced directly from accredited pharmaceutical-grade manufacturers, avoiding counterfeit or expired products common on third-party online marketplaces.
A note on deprescribing antidepressants
Much is currently being said about the perceived dangers of antidepressants and SSRIs, especially the difficulty that can come from stopping them. While these medications can and do help many people, it is also true that they can cause unwanted physical symptoms soon or long after discontinuing them.
Beyond supplemental approaches, I have written previously about the “Prozac Bridge Method” of transitioning off of other antidepressants, which should only be attempted under a physician’s supervision.